Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 5/2020

THE EFFECT OF PIOGLITAZONE ON INTIMAL HYPERPLASIA OF VENOUS BRIDGE VASCULAR

HONGGUANG LU 1, SHUANG LI 2, YANKUN HAO 2, GUANGNAN LI 3, FUBO ZHOU 4*

1.Department of Cardiovascular Surgery, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, 150001, China
2 .Medical Functional Laboratory, Mudanjiang Medical University, Mudanjiang,157011, China
3 .Department of Cardiology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, 150001, China
4 .Department of Pharmacology, Mudanjiang Medical University, Mudanjiang, 157011, China

Download Full Article PDF

This study aimed to analyse the effect of pioglitazone (PIO) on intimal hyperplasia of venous bridge vascular using a murine model of vein transplantation. The rats were treated with 3 mg/kg bw PIO one week before modelling and for 2 and 4 weeks after modelling. The thickness and changes of vascular intima were analysed by histopathology and the expression of phosphorylated extracellular signal-regulated kinase (p-ERK1/2) protein in rat venous bridges was detected by Western blotting. The results showed that the blood vessels in the model group at 2 and 4 weeks after modelling (NC4) had a significantly increased membrane thickness ratio compared with the sham-operated group (NO4). PIO treatment significantly decreased the membrane thickness ratio and the venous bridge cell components compared with the model group indicating that PIO could inhibit the intima thickening of the venous bridge. Regarding the p-ERK1/2 levels, PIO treatment significantly decreases the upregulation of p-ERK1/2 observed in the model group. Therefore, it can be concluded that PIO could effectively alleviate intimal hyperplasia after venous bridge vascular transplantation, and inhibit the expression of p-ERK1/2 and the proliferation of vascular smooth muscle cells (VSMCs).